Bionano Genomics, Inc. (Nasdaq: BNGO) today announced its 2024
Symposium, the quintessential event for the optical genome mapping
(OGM) community. The event is an opportunity for OGM users to
present their progress to the world. 2024 Symposium will feature
four consecutive days of OGM presentations delivered by 27
different customers worldwide across a wide range of applications
in cancer, cell and gene therapy, and constitutional genetic
disease. The Symposium will take place virtually from January
22 to 25, 2024. Each day will feature user presentations, a live
panel with Q&A, and scientific posters within the virtual
exhibition hall. On day 2, Bionano will unveil a new product
expected to advance cytogenetics and structural variant analysis.
“At Bionano, we are working to transform the way the world sees
the genome,” said Erik Holmlin, PhD, president and chief
executive officer of Bionano. “Symposium is our platform event for
the community of OGM users to share their experiences with OGM and
how it can be used to reveal more answers for research
applications. What impresses me most about the lineup for 2024 is
the sheer breadth of topics, ranging from the use of OGM in
prenatal and postnatal testing, to homologous recombination
deficiency (HRD) analysis in breast cancer and the use of OGM in
drug development through cell and gene therapy.”
“We were thrilled with the engagement of the OGM community at
2023 Symposium, with participants from 114 different countries. We
believe our customers around the world have made tremendous
progress with the implementation of OGM in their laboratories since
last year. The lineup of researchers for our 2024 Symposium is our
most exciting to date, with 27 global experts detailing their use
of OGM to drive discoveries across a number of clinical research
applications,” said Alka Chaubey, PhD, FACMG, chief medical
officer at Bionano.
Each session of 2024 Symposium will start at 7:00 am
PST and will last approximately 3 hours. After the scientific
presentations, the speakers will join a live panel discussion and
Q&A moderated by Dr. Chaubey. In addition, each day will
feature a scientific poster exhibit. Below is an overview of the
presentation topics for each day of the event.
Monday, January 22: New Standards in Hematological
Malignancies
Global researchers studying genomic variants involved in
hematologic malignancies will discuss their experience publishing a
framework to guide OGM implementation as part of an international
consortium. Speakers will also highlight the use of new tools,
including VIA™ software, to find more pathogenic chromosomal
aberrations in hematological malignancy samples while also
simplifying laboratory workflows.
Tuesday, January 23: New Frontiers in
OncologyScientists and clinicians from leading hospitals
and medical research institutions in the United States,
India and Europe will discuss OGM’s utility for the
assessment of genomic aberrations in a wide range of hematological
malignancies and solid tumors. Experts will present results from a
prospective study on the use of OGM in hematological malignancy
samples. The final presentation of the day will feature Bionano
leadership unveiling a major new product, followed by a live
discussion and question and answer session.
Wednesday, January 24: Advances in Constitutional
ApplicationsResearchers will present their experiences
using OGM to uncover genetic variation that contributes to rare
undiagnosed genetic disease, developmental disorders and
reproductive disorders. Presentations will demonstrate how the
analysis of structural variation data from OGM may increase the
likelihood of identifying actional pathogenic variants that can
help solve unresolved cases. Data from large multi-site studies
focusing on prenatal and postnatal applications will be
presented.
Thursday, January 25: OGM in Cell and Gene
TherapyPresentations will center on OGM’s potential to
serve as a genomic integrity tool for cell and gene therapy
applications, supporting the development of in vivo gene therapies.
Panelists will cover OGM’s ability to screen cell lines for genomic
instability and off-target events associated with genome
editing.
2024 Symposium registration is open to all and there is no
charge for attending this event. Register today
at https://bionanosymposium2024.vfairs.com/.
About Bionano
Bionano is a provider of genome analysis solutions that can
enable researchers and clinicians to reveal answers to challenging
questions in biology and medicine. The Company’s mission is to
transform the way the world sees the genome through OGM solutions,
diagnostic services and software. The Company offers OGM solutions
for applications across basic, translational and clinical research.
Through its Lineagen, Inc. d/b/a Bionano
Laboratories business, the Company also provides diagnostic
testing for patients with clinical presentations consistent with
autism spectrum disorder and other neurodevelopmental disabilities.
The Company also offers an industry-leading, platform-agnostic
software solution, which integrates next-generation sequencing and
microarray data designed to provide analysis, visualization,
interpretation and reporting of copy number variants,
single-nucleotide variants and absence of heterozygosity across the
genome in one consolidated view. The Company additionally offers
nucleic acid extraction and purification solutions using
proprietary isotachophoresis technology. For more information,
visit www.bionano.com, www.bionanolaboratories.com or www.purigenbio.com.
Unless specifically noted otherwise, Bionano’s OGM products
are for research use only and not for use in diagnostic
procedures.
Forward-Looking Statements of
Bionano
This press release contains forward-looking statements contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Words such as “believe,”
“can,” “may,” “potential,” “will” and similar expressions (as well
as other words or expressions referencing future events, conditions
or circumstances and the negatives thereof) convey uncertainty of
future events or outcomes and are intended to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things,
the anticipated benefits of the 2024 Symposium, the potential for
OGM to be adopted for applications discussed at the 2024 Symposium,
and the ability and utility of OGM to be adopted as a cytogenetic
tool for analysis of oncology, including heme malignancies and
solid tumors, constitutional genetic diseases or samples associated
with cell bioprocessing and other applications discussed at the
2024 Symposium. Each of these forward-looking statements involves
risks and uncertainties. Actual results or developments may differ
materially from those projected or implied in these forward-looking
statements. Factors that may cause such a difference include the
risks and uncertainties associated with: the impact of geopolitical
and macroeconomic developments, such as recent and future bank
failures, the ongoing Ukraine-Russia conflict, related sanctions,
the Israel-Hamas war, and any global pandemics, on our business and
the global economy; challenges inherent in developing,
manufacturing and commercializing products; our ability to further
deploy new products and applications and expand the markets for our
technology platforms; changes in the competitive landscape and the
introduction of competitive technologies or improvements to
existing technologies; failure of future study results to support
those reported and discussed at the 2024 Symposium; future study
results that contradict the results discussed and reported at the
2024 Symposium; failure of OGM to be adopted as a cytogenetic tool
for analysis of oncology, including heme malignancies and solid
tumors, constitutional genetic diseases or samples associated with
cell bioprocessing and other applications discussed at the 2024
Symposium; changes in our strategic and commercial plans; our
ability to obtain sufficient financing to fund our strategic plans
and commercialization efforts; the ability of medical and research
institutions to obtain funding to support adoption or continued use
of our technologies; and the risks and uncertainties associated
with our business and financial condition in general; our
expectations and beliefs regarding future growth of the business
and the markets in which we operate; changes in our strategic and
commercial plans; our ability to obtain sufficient financing to
fund our strategic plans and commercialization efforts and our
ability to continue as a “going concern”; and including the risks
and uncertainties described in our filings with the Securities and
Exchange Commission, including, without limitation, our Annual
Report on Form 10-K for the year ended December 31, 2022 and in
other filings subsequently made by us with the Securities and
Exchange Commission. All forward-looking statements contained in
this press release speak only as of the date on which they were
made and are based on management’s assumptions and estimates as of
such date. We are under no duty to update any of these
forward-looking statements after the date they are made to conform
these statements to actual results or revised expectations, except
as required by law. You should, therefore, not rely on these
forward-looking statements as representing our views as of any date
subsequent to the date the statements are made. Moreover, except as
required by law, neither we nor any other person assumes
responsibility for the accuracy and completeness of the
forward-looking statements contained in this press release.
CONTACTS
Company Contact:Erik Holmlin, CEOBionano
Genomics, Inc.+1 (858) 888-7610eholmlin@bionano.com
Investor Relations:David HolmesGilmartin
Group+1 (858) 888-7625IR@bionano.com
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Bionano Genomics (NASDAQ:BNGO)
Historical Stock Chart
From Apr 2023 to Apr 2024